Dyslipidemia and inflammation in patients with inflammatory bowel disease.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed.

1. Cardiovascular disease: extraintestinal manifestation of inflammatory bowel disease.Intestinal research · 2025
   Review
2. Evaluating the triglyceride-glucose index as a biomarker for inflammatory bowel disease risk: insights from a UK Biobank prospective study.Frontiers in immunology · 2025
   Article
3. Berberine Suppresses Colonic Inflammation in Dextran Sulfate Sodium-Induced Murine Colitis Through Inhibition of Cytosolic Phospholipase A2 Activity.Frontiers in pharmacology · 2020
   Article
4. Care of inflammatory bowel disease patients in remission.Gastroenterology report · 2016
   Review
5. Cardiovascular complications in inflammatory bowel disease.Current drug targets · 2015
   Review

Corrections and comments

• Comment on
  The fatty acid profile of the erythrocyte membrane in initial-onset inflammatory bowel disease patients.2013

Authors and funding

4 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as